Key result
LU 135252 reduces RV pressure ~35% vs saline in rats with pulmonary hypertension.
Why the study?
Does the ETA-receptor antagonist LU 135252 improve survival and pulmonary hemodynamics in rats with established monocrotaline-induced pulmonary hypertension?
Does the ETA-receptor antagonist LU 135252 improve survival and pulmonary hemodynamics in rats with established monocrotaline-induced pulmonary hypertension?
Answers are grounded in this paper and cite their sources.
In a rat model of established pulmonary hypertension, ETA-receptor antagonism with LU 135252 improved pulmonary hemodynamics and right ventricular hypertrophy.
BACKGROUND: An imbalance between the nitric oxide (NO) and endothelin systems may contribute to the development of pulmonary hypertension (PH). We evaluated the effect of the specific ET(A)-receptor antagonist LU 135252 (LU) in rats with established monocrotaline (MCT)-induced PH and the involvement of NO in the control of pulmonary vascular tone. METHODS AND RESULTS: Two weeks after MCT, rats developed PH with a right ventricular pressure (RVP) of 42.3 +/- 8.5 vs 28.2 +/- 4.1 mmHg for controls (mean +/- SD, P <.05). Daily oral therapy with LU (50 mg/kg) or saline was started 2 weeks post-MCT injection for 20 days. LU increased the survival rate nonsignificantly from 41.7% to 66.7%. The surviving MCT + saline rats showed severe PH (RVP of 82.5 +/- 8.9 mmHg) and RV hypertrophy with a right-to-left ventricle + septum weight ratio of 69.6% +/- 10.2%, which were improved by LU to 53.5 +/- 11.1 mmHg and 53.7% +/- 9.9%, respectively (P <.01). In isolated lungs, pulmonary vascular compliance was reduced by PH and unaffected by LU therapy. After the NO synthase inhibitor N(omega)-nitro-L-arginine (10(-4) mol/L), compliance was further reduced, although much less so, in the LU-treated group (P <.01). CONCLUSIONS: In this model, ET(A) antagonist therapy has a favorable effect on survival and pulmonary hemodynamics and reduces the dependency on NO for the attenuation of reduced vascular compliance.
No takes yet. Share an insight, caveat, or question.
Dupuis et al. (1999) studied Monocrotaline-induced pulmonary hypertension. LU 135252 vs. Saline was evaluated on Right ventricular pressure (mmHg) (p=<.01). In rats with established monocrotaline-induced pulmonary hypertension, daily oral therapy with LU 135252 reduced right ventricular pressure compared to saline.
Synapse has enriched 10 related papers. Consider them for comparative context: